AI in drug discovery – what it is, where we stand and the path forward

That matched the lived experience from people doing the work. A structural biologist said AI already saves real time on scripting, debugging, software setup, experiment checks, and generating starting structural models with tools like AlphaFold. That is a real productivity gain. It is not the same as discovering mechanisms or compounds humans could not have found before. Others pushed the same distinction more bluntly. Discovery was never the main bottleneck by itself. Biology is messy, validation is slow, and drug development timelines are longer than the recent wave of effective AI tools, so strong outcome data will lag for years. The useful consensus was practical. AI in this domain looks strongest as force multiplication for scientists, not as an autonomous inventor. People also liked Lowe’s piece because it translated a paywalled review into plain language and resisted the usual biotech AI marketing fog. The sharpest caution was that investors and operators should demand testable claims and comparable benchmarks, because a lot of the industry narrative still bundles together workflow acceleration, model demos, and actual therapeutic progress as if they were the same thing.